Sen. Markwayne Mullin Sells Off Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Senator Markwayne Mullin (R-Oklahoma) recently sold shares of Thermo Fisher Scientific Inc. NYSE: TMO. In a filing disclosed on May 12th, the Senator disclosed that they had sold between $50,001 and $100,000 in Thermo Fisher Scientific stock on April 8th.

Senator Markwayne Mullin also recently made the following trade(s):

• Sold $15,001 - $50,000 in shares of Texas Instruments NASDAQ: TXN on 4/8/2025.
• Sold $15,001 - $50,000 in shares of CSX NASDAQ: CSX on 4/8/2025.
• Sold $50,001 - $100,000 in shares of Lam Research NASDAQ: LRCX on 4/8/2025.
• Sold $15,001 - $50,000 in shares of Chevron NYSE: CVX on 4/8/2025.
• Sold $15,001 - $50,000 in shares of Zoetis NYSE: ZTS on 4/8/2025.
• Sold $15,001 - $50,000 in shares of ConocoPhillips NYSE: COP on 4/8/2025.
• Sold $50,001 - $100,000 in shares of Applied Materials NASDAQ: AMAT on 4/8/2025.
• Sold $15,001 - $50,000 in shares of Adobe NASDAQ: ADBE on 4/8/2025.
• Sold $50,001 - $100,000 in shares of Valero Energy NYSE: VLO on 4/8/2025.
• Purchased $15,001 - $50,000 in shares of Capital One Financial NYSE: COF on 3/19/2025.

Thermo Fisher Scientific Stock Up 1.8%

Thermo Fisher Scientific stock traded up $7.22 during trading on Friday, reaching $412.15. 2,498,185 shares of the company's stock were exchanged, compared to its average volume of 1,840,883. The company's 50-day moving average is $453.88 and its two-hundred day moving average is $509.89. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.29 and a current ratio of 1.66. Thermo Fisher Scientific Inc. has a 52-week low of $390.50 and a 52-week high of $627.88. The firm has a market cap of $155.58 billion, a price-to-earnings ratio of 24.93, a PEG ratio of 2.99 and a beta of 0.82.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $5.15 EPS for the quarter, topping analysts' consensus estimates of $5.10 by $0.05. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. The firm had revenue of $10.36 billion for the quarter, compared to analyst estimates of $10.23 billion. During the same quarter in the previous year, the business posted $5.11 EPS. The firm's revenue was up .2% compared to the same quarter last year. On average, analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, April 15th. Investors of record on Friday, March 14th were given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 0.42%. This is a boost from Thermo Fisher Scientific's previous quarterly dividend of $0.39. The ex-dividend date of this dividend was Friday, March 14th. Thermo Fisher Scientific's dividend payout ratio is 10.09%.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Stonegate Investment Group LLC boosted its holdings in Thermo Fisher Scientific by 0.3% during the fourth quarter. Stonegate Investment Group LLC now owns 6,788 shares of the medical research company's stock worth $3,531,000 after buying an additional 18 shares in the last quarter. Semus Wealth Partners LLC boosted its holdings in Thermo Fisher Scientific by 4.0% during the fourth quarter. Semus Wealth Partners LLC now owns 471 shares of the medical research company's stock worth $245,000 after buying an additional 18 shares in the last quarter. Eagle Rock Investment Company LLC boosted its holdings in Thermo Fisher Scientific by 0.3% during the fourth quarter. Eagle Rock Investment Company LLC now owns 7,463 shares of the medical research company's stock worth $3,882,000 after buying an additional 19 shares in the last quarter. KRS Capital Management LLC boosted its holdings in Thermo Fisher Scientific by 1.5% during the fourth quarter. KRS Capital Management LLC now owns 1,317 shares of the medical research company's stock worth $685,000 after buying an additional 20 shares in the last quarter. Finally, Evernest Financial Advisors LLC lifted its position in shares of Thermo Fisher Scientific by 4.0% in the 4th quarter. Evernest Financial Advisors LLC now owns 521 shares of the medical research company's stock valued at $271,000 after acquiring an additional 20 shares in the last quarter. 89.23% of the stock is currently owned by institutional investors.

Insider Activity at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction that occurred on Tuesday, March 4th. The shares were sold at an average price of $516.67, for a total value of $5,166,700.00. Following the completion of the sale, the chief executive officer now owns 115,174 shares in the company, valued at $59,506,950.58. This represents a 7.99% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Gianluca Pettiti sold 300 shares of the stock in a transaction that occurred on Monday, April 28th. The stock was sold at an average price of $429.93, for a total transaction of $128,979.00. Following the completion of the sale, the executive vice president now owns 23,167 shares of the company's stock, valued at approximately $9,960,188.31. The trade was a 1.28% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 14,075 shares of company stock worth $7,305,942. 0.33% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on TMO shares. Barclays cut their price objective on shares of Thermo Fisher Scientific from $620.00 to $475.00 and set an "equal weight" rating on the stock in a report on Thursday, April 10th. Morgan Stanley upped their target price on shares of Thermo Fisher Scientific from $647.00 to $678.00 and gave the company an "overweight" rating in a research note on Friday, January 31st. UBS Group cut their target price on shares of Thermo Fisher Scientific from $715.00 to $500.00 and set a "buy" rating on the stock in a research note on Thursday, April 24th. StockNews.com downgraded shares of Thermo Fisher Scientific from a "buy" rating to a "hold" rating in a research report on Friday, April 25th. Finally, Evercore ISI lowered their price objective on shares of Thermo Fisher Scientific from $585.00 to $500.00 and set an "outperform" rating for the company in a research report on Thursday, April 24th. Five analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $607.43.

About Senator Mullin

Markwayne Mullin (Republican Party) is a member of the U.S. Senate from Oklahoma. He assumed office on January 11, 2023. His current term ends on January 3, 2027. Mullin (Republican Party) ran in a special election to the U.S. Senate to represent Oklahoma. He won in the special general election on November 8, 2022. Mullin is a member of the Cherokee Nation and one of four Native American members of the 116th Congress. At the age of 20, Mullin took over his father's plumbing business. He is also a former professional mixed martial artist. Markwayne Mullin graduated from Stilwell High School. Mullin earned an associate degree in construction technology from Oklahoma State University Institute of Technology. His career experience includes owning and founding multiple businesses.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.